A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
A phase 1/2 trial of GNC-035 in chronic lymphocytic leukaemia, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies is a phase 1/2 interventional study registered as NCT05944978 by Sichuan Baili Pharmaceutical Co., Ltd., with 3 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2025-12. Interventions recorded: GNC-035.
Similar pages
not linked directly; found by shared links- TrialA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Shares SystImmune / Sichuan Biokin and the tag pipeline.